¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Heart Function Tests"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • fetal heart rate
    žƽɹڼö
  • fetal heart sound
    žƽÉ(Àå)À½
  • first heart sound
    Á¦1½É(Àå)À½
  • flask shaped heart
    Çöó½ºÅ©½ÉÀå
  • forward heart failure
    ¾ÕÂʽÉÀå±â´É»ó½Ç, ÀüÇâ½É(Àå)ºÎÀü
  • four chambered heart
    ³×¹æ½ÉÀå
  • fourth heart sound
    Á¦4½É(Àå)À½
  • globular heart
    °ø¸ð¾ç½ÉÀå, ±¸»ó½ÉÀå
  • hypertensive heart disease
    °íÇ÷¾Ð½ÉÀ庴, °íÇ÷¾Ð½ÉÀåÁúȯ
  • hypertrophic heart
    ºñ´ë½ÉÀå
  • hypoplastic heart
    Çü¼ºÀúÇϽÉÀå
  • hypoxic heart failure
    Àú»ê¼Ò½ÉÀå±â´É»ó½Ç, Àú»ê¼Ò½É(Àå)ºÎÀü
  • heart
    ½ÉÀå, ½É
  • heart atrium
    ½É¹æ
  • heart block
    ½ÉÀåÂ÷´Ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • beriberi heart
    °¢±â½ÉÀå
  • boot shaped heart
    ÀåÈ­½ÉÀå
  • fetal heart beat
    žƽÉÀå¹Úµ¿
  • heart block
    ½ÉÀåÂ÷´Ü
  • heart burn
    °¡½¿¾ÎÀÌ
  • intraatrial heart block
    ½É¹æ³»Â÷´Ü
  • unidirectional heart block
    ÇѹæÇâ½ÉÀåÂ÷´Ü
  • carcinoid heart disease
    À¯¾Ï½ÉÀ庴
  • congenital heart disease
    ¼±Ãµ½ÉÀ庴
  • congestive heart failure
    ¿ïÇ÷½ÉÀå±â´É»ó½Ç, ¿ïÇ÷½ÉºÎÀüÁõ
  • constrictive heart disease
    ±³Âø½ÉÀ庴
  • heart disease
    ½ÉÀ庴
  • heart muscle disease
    ½ÉÀå±ÙÀ°º´
  • hypertensive heart disease
    °íÇ÷¾Ð½ÉÀ庴, °íÇ÷¾Ð½ÉÀåÁúȯ
  • ischemic heart disease
    ÇãÇ÷½ÉÀåÁúȯ, ÇãÇ÷½ÉÀ庴
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • artificial heart
    Àΰø½É(Àå)(¡­½ÉÀå).
  • artificial heart
    Àΰø½É(Àå)(¡­ãýíô).
  • artificial heart lung
    Àΰø½ÉÆó(¡­½ÉÆó).
  • artificial heart lung machine
    Àΰø½ÉÆó±â.
  • four chambered heart
    ³×¹æ½ÉÀå
  • fourth heart sound
    Á¦»ç½ÉÀ½(ð¯ÞÌãýëå).
  • globular heart
    ±¸»ó½ÉÀå.
  • heart
    ½ÉÀå
  • heart atrium
    ½É¹æ(ãýÛ®).
  • heart beat
    ½É¹Ú(µ¿)(ãýÚÑÔÑ).
  • heart block
    ½ÉÂ÷´Ü.
  • heart block
    ½ÉÂ÷´Ü.
  • heart burn
    °¡½¿¾²¸², °¡½¿¾ÎÀÌ
  • heart catheterization
    ½É(Àå)Ä«Å×Å׸£¹ý.
  • heart death
    ½ÉÀå»ç(ãýíôÞÝ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • liver function test
    °£±â´É°Ë»ç(ÊÜѦÒöËþÞÛ).
  • localization of function
    ±â´É±¹Àç(ѦÒöÏÑî¤).
  • logarithmic function
    ·Î±×ÇÔ¼ö(ÊṴ̀Ëà).
  • metabolic function
    ´ë»ç±â´É(¡­Ñ¦Òö).
  • mixed function oxidase
    È¥ÇÕ±â´É¿Á½Ãµ¥À̽º.
  • mixed function oxidase
    º¹ÇÕ±â´É»êÈ­È¿¼Ò(ÜÜùêѦÒöß«ûùý£áÈ).
  • moment generating function
    Àû·ü¸ðÇÔ¼ö, ¸ð¸àÆ®¸ðÇÔ¼ö(¡­Ù½ùÞâ¦).
  • monotonous function
    ´ÜÁ¶ÇÔ¼ö(Ó¤ðàùÞâ¦).
  • multiplicative function
    ½Â¹ýÇÔ¼ö(ËàËÑ̰Ëà).
  • municipal health function
    µµ½Ãº¸°Ç±â´É(ËÄËàËÓ˧˻ËÀ).
  • myocardial function
    ½É±Ù±â´É.
  • olfactory function
    Èİ¢ÀÛ¿ë
  • p-450 mixed function oxidase
    P-450º¹ÇÕ±â´É»êÈ­È¿¼Ò(¡­ùêѦÒöß«ûùý£áÈ)
  • pancreatic function test
    ÃéÀå±â´É½ÃÇè(õýíô ѦÒöãËúÐ).
  • partition function
    ºÐ¹èÇÔ¼ö.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NYHA New York Heart Association
  Heart Disease¿¡ ´ëÇÑ Functional Classification
 &nbs...
AHA acetohydroxamic acid; acquired hemolytic anemia; acute hemolytic anemia; American Heart Association;...
ASHD arteriosclerotic heart disease; atrioseptal heart disease
CHB chronic hepatitis B; complete heart block; congenital heart block
CHF chick embryo fibroblast; chronic heart failure; congenital hepatic fibrosis; congestive heart failur...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ECF Extracytoplasmic function
gf Gain-of-function
GMFM Gross Motor Function Measure
HRTF head-related transfer function
IIEF International Index of Erectile Function
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cyanotic heart disease
    û»ö¼º ½ÉÀå Áúȯ
  • eyeball-heart reflex
    ¾È±¸ ½ÉÀå ¹Ý»ç
  • heart
    ½ÉÀå
    Ç÷¾× ¼øÈ¯À» °üÀåÇÏ´Â ½É±Ù¼º ±â°ü. 4°³ÀÇ °­µ¿, 2°³ÀÇ ½É½Ç°ú 2°³ÀÇ ½É¹æÀ¸·Î ³ª´²Áø´Ù.
  • heart beat
    ½É¹Úµ¿
    ½ÉÀåÀÌ È°µ¿ÇÏ´Â ¿òÁ÷ÀÓ.
  • heart burn
    °¡½¿¾ÎÀÌ
    Èä°ñ ÈĺÎÀÇ ÀÛ¿­°¨. »ê¼º ¾Ö±â¶ó°íµµ ÇÑ´Ù. º¸Åë ½Äµµ¿¡ »êÀÇ ¿ª·ù·Î »ý±ä´Ù.
  • heart disease
    ½ÉÀå º´, ½É Áúȯ
    ¼øÈ¯±â Áúȯ Áß ½ÉÀåÀÇ Áúȯ. ÀϹÝÀûÀ¸·Î °ü Ç÷°üÀ̳ª ½ÉÀåÀÇ º´µµ Æ÷ÇԵȴÙ. º´º¯ÀÇ ºÎÀ§¿¡ ÀÇÇÑ º´¸®ÇغÎÇÐÀû ºÐ·ù¿Í º´Àο¡ ÀÇÇÑ ºÐ·ù°¡ ÀÌ·ç¾îÁö°í ÀÖ´Ù. ÀüÀÚ´Â ¼ö ½Ê ³â ÀüºÎÅÍ ¾²¿©Á® ¿ÔÀ¸³ª ±Ù³â¿¡ ¿Í¼­ º»ÁúÀûÀÎ ¿øÀÎ ¿ä¹ýÀÌ °¡´ÉÇÏ°Ô µÈ ÀÌÈÄ´Â ÈÄÀÚÀÇ ºÐ·ù°¡ ÀÇÀǰ¡ À־ ¸¹ÀÌ ¾²ÀÌ°Ô µÇ¾ú´Ù. º´º¯ ºÎÀ§·Î´Â ½É³»¸·
  • heart failure
    ½ÉºÎÀü
    ½É ¹ÚÃâ·®ÀÇ Àå¾Ö ¶Ç´Â Á¤¸Æ¾ÐÀÇ »ó½ÂÀ¸·Î ¹ß»ýÇϴ ƯÀ¯ÇÑ ÀÚ°¢Àû ¹× Ÿ°¢Àû Áõ»óÀ» Ư¡À¸·Î ÇÏ´Â ÀÓ»óÀû ÁõÈıº. ½É½Ç È®À强ÀÇ ¾Ð·Â Áõ´ë¿Í Àü½ÅÀÇ Çʿ䷮¿¡ ºÎÁ·ÇÑ ½É ¹ÚÃâ·®À» ¼ö¹ÝÇÏ´Â ½É±Ù ºÎÀü¿¡ ´ëÇÏ¿© °¡Àå ºó¹øÇÏ°Ô »ç¿ëµÇ´Â ¸»ÀÌ´Ù. Àü½Å Á¤¸Æ ¶Ç´Â Æó Á¤¸ÆÀÇ ¾î´À ÂÊÀÇ È®ÀåÀÌ ´õ¿í ½ÉÇѰ¡¿¡ µû¶ó ¿ìÃø ½ÉºÎÀü ȤÀº ÁÂÃø ½ÉºÎÀüÀ¸·Î ¼¼ºÐµÉ ¶§°¡ ¸¹´Ù.
  • heart lung machine
    ½ÉÆó±â, Àΰø ½ÉÆó ÀåÄ¡±â
    µ¿¸Æ ÆßÇÁ. Ç÷¾×À» »ê¼Ò·Î Æ÷È­Çϱâ À§ÇÑ ÀåÄ¡·Î µ¿¸Æ ÆßÇÁ ¹× ¿©°ú±â¿Í Àú·ùÁ¶°¡ ºÙÀº Ç÷¾× ÇÊÅÍ¿Í Àú·ùÁ¶·Î ÀÌ·ç¾îÁø ±â±¸·Î, ü¿Ü ¼øÈ¯À¸·Î¼­, ½ÉÀå ¼ö¼úÀÇ °æ¿ì¿¡ ½ÉÀå°ú ÆóÀÇ ±â´ÉÀ» ´ëÇàÇϱâ À§ÇÏ¿© »ç¿ëÇÑ´Ù.
  • heart murmur
    ½É ÀâÀ½
    ½ÉÇ÷°ü°è ÁúȯÀ» °¡Áø ȯÀÚ¿¡ ´ëÇÑ Ã»Áø½Ã µé¸®´Â ¼Ò¸®.
  • heart palpitation
    ½É°è Ç×Áø
    Áúº´, ÈïºÐ, °ú·Î µîÀ¸·Î ½ÉÀåÀÇ °íµ¿ÀÌ ³ô¾ÆÁö´Â ÀÏ.
  • heart rate meter
    ½É¹Ú°è, ½ÉÀå ¹Úµ¿°è, ½É¹Úµ¿°è
  • heart sac
    ½É¸·
    ½ÉÀå°ú ´ëÇ÷°ü ±âÀúºÎ¸¦ µÑ·¯½Î´Â ¼¶À¯ À帷¼ºÀÇ ³¶À¸·Î, ¼¶À¯ Á¶Á÷À¸·Î µÈ ¿ÜÃþ°ú À帷À¸·Î µÈ ³»ÃþÀ¸·Î ±¸¼ºµÇ¸ç, ½É¸·ÀÇ ±âÀúºÎ´Â Ⱦ°Ý¸·ÀÇ °Ç Á߽ɿ¡ ºÎÂøµÇ¾î ÀÖ´Ù.
  • heart septal defect
    ½É Áß°Ý °á¼Õ, ½É Áß°Ý °á¼ÕÁõ
  • heart stroke
    ½É °íµ¿, Çù½ÉÁõ
  • hyperkinetic heart syndrome
    °ú¿îµ¿¼º ½ÉÁõÈÄ, °ú¿îµ¿¼º ½ÉÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
carcinogenicity tests Tests to experimentally measure the tumour-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumours or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumour developed. Though this test differs from the DNA-repair and bacterial microsome mutagenicity tests, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
(12 Dec 1998)
gel diffusion precipitin tests Precipitin test's in which the immune precipitate forms in a gel medium (usually agar) into which one or both reactants have diffused; generally classified in two types, in one dimension, and in two dimensions.
Synonym: gel diffusion reactions.
(05 Mar 2000)
gel diffusion precipitin tests in one dimension Precipitin test's in which antigen solution and antibody incorporated in agar are layered in tubes, permitting effective diffusion in the vertical dimension; the antibody-containing agar may be overlaid directly with antigen solution (single (gel) diffusion in one dimension).
(05 Mar 2000)
gel diffusion precipitin tests in two dimensions Precipitin test's made in a layer of agar that permits radial diffusion, in both of the horizontal dimensions, of one or both reactants. Double (gel) diffusion in two dimensions (Ouchterlony test, technique, or method) incorporates antigen and antibody solutions placed in separate wells in a sheet of plain agar, permitting radial diffusion of both reactants; this method is widely used to determine antigenic relationships; the bands of precipitate that form where the reactants meet in optimal concentration are of three patterns, referred to as reaction of identity, reaction of partial identity (cross-reaction), and reaction of nonidentity.
(05 Mar 2000)
patch tests Skin tests in which the sensitiser is applied to a patch of cotton cloth or gauze held in place for approximately 48-72 hours. It is used for the elicitation of a contact hypersensitivity reaction.
(12 Dec 1998)
personality tests Standardised objective tests designed to facilitate the evaluation of personality.
(12 Dec 1998)
microbial sensitivity tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
(12 Dec 1998)
micronucleus tests Induction and quantitative measurement of chromosomal damage leading to the formation of micronuclei in cells which have been exposed to genotoxic agents or ionizing radiation.
(12 Dec 1998)
clinical chemistry tests Laboratory tests demonstrating the presence of physiologically significant substances in the blood, urine, tissue, and body fluids with application to the diagnosis or therapy of disease.
(12 Dec 1998)
complement fixation tests Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualised by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (haemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
(12 Dec 1998)
word association tests Lists of words to which individuals are asked to respond ascertaining the conceptual meaning held by the individual.
(12 Dec 1998)
mutagenicity tests Tests of chemical substances and physical agents for mutagenic potential. They include microbial, insect, mammalian cell, and whole animal tests.
(12 Dec 1998)
haemagglutination inhibition tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of haemagglutination.
(12 Dec 1998)
haemagglutination tests Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes.
(12 Dec 1998)
haematologic tests Tests used in the analysis of the hemic system.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á